Table 7.
Recommendation for MIC of 2 mg/L.
| CrCl (mL/min) | Regimens (TDDs) | PTA (%) | AKI Risk (%) | Alternative Regimens (TDDs) | PTA (%) | AKI Risk (%) | ||
|---|---|---|---|---|---|---|---|---|
| EOT | D7 | EOT | D7 | |||||
| 101–130 | Not recommend | |||||||
| 80–100 | 120 mg Q6h (480 mg) | 79.23 | 66.74 | 54.62 | ||||
| 51–79 | 120 mg Q8h (360 mg) | 80.15 | 65.75 | 54.22 | 180 mg Q12h (360 mg) | 79.6 | 59.64 | 48.22 |
| 30–50 | 120 mg Q12h (240 mg) | 84.77 | 67.98 | 54.81 | 250 mg Q24h (250 mg) | 85.6 | 47.49 | 37.15 |
| 11–29 | 120 mg Q24h (120 mg) | 81.28 | 45.21 | 33.16 | ||||
| 1–10 | 80 mg Q24h (80 mg) | 84.16 | 52.76 | 39.14 | ||||
TDDs*: total daily doses in mg of colistin base activity, Q: every, PTA: probability of target attainment, CFR: cumulative fraction of response, AKI: acute kidney injury, CrCl: creatinine clearance, MIC: minimum inhibitory concentration, EOT: end of treatment, D7: at day 7.